Clinical applications of growth factors in bone injuries: Experience with BMPs

Mario Ronga; Alessandro Fagetti; Gianluca Canton; Elia Paiusco; Michele Francesco Surace; Paolo Cherubino

doi:10.1016/S0020-1383(13)70008-1

Clinical applications of growth factors in bone injuries: Experience with BMPs

Mario Ronga, Alessandro Fagetti, Gianluca Canton, Elia Paiusco, Michele Francesco Surace, Paolo Cherubino

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

The management of open fractures and delayed or non unions continue to be complicated by high rates of treatment failure and significant patient disability and dissatisfaction. The use of bone morphogenetic proteins (BMPs) in the treatment of these injuries has been assessed by several authors. BMPs induce the process of bone healing by recruiting bone-forming cells to the area of lesion. The use of BMP currently has two FDA-approved indications: treatment of open tibial fractures treated with intramedullary fixation and treatment of tibia long bone non-union. Despite this limited target, off-label BMP use continues to push the spectrum for new applications. This review describes the current evidence for the use of BMPs in open fractures and non-unions.

Lingua originale	Inglese
pagine (da-a)	S34-S39
Rivista	Injury
Volume	44
Numero di pubblicazione	SUPPL.1
DOI	https://doi.org/10.1016/S0020-1383(13)70008-1
Stato di pubblicazione	Pubblicato - gen 2013
Pubblicato esternamente	Sì

Accesso al documento

10.1016/S0020-1383(13)70008-1

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{b30a96c8749a489ba542606104138392,

title = "Clinical applications of growth factors in bone injuries: Experience with BMPs",

abstract = "The management of open fractures and delayed or non unions continue to be complicated by high rates of treatment failure and significant patient disability and dissatisfaction. The use of bone morphogenetic proteins (BMPs) in the treatment of these injuries has been assessed by several authors. BMPs induce the process of bone healing by recruiting bone-forming cells to the area of lesion. The use of BMP currently has two FDA-approved indications: treatment of open tibial fractures treated with intramedullary fixation and treatment of tibia long bone non-union. Despite this limited target, off-label BMP use continues to push the spectrum for new applications. This review describes the current evidence for the use of BMPs in open fractures and non-unions.",

keywords = "Bone morphogenetic protein (BMP), Fracture healing, Non-union, Open fracture",

author = "Mario Ronga and Alessandro Fagetti and Gianluca Canton and Elia Paiusco and Surace, {Michele Francesco} and Paolo Cherubino",

year = "2013",

month = jan,

doi = "10.1016/S0020-1383(13)70008-1",

language = "English",

volume = "44",

pages = "S34--S39",

journal = "Injury",

issn = "0020-1383",

publisher = "Elsevier Ltd.",

number = "SUPPL.1",

}

TY - JOUR

T1 - Clinical applications of growth factors in bone injuries

T2 - Experience with BMPs

AU - Ronga, Mario

AU - Fagetti, Alessandro

AU - Canton, Gianluca

AU - Paiusco, Elia

AU - Surace, Michele Francesco

AU - Cherubino, Paolo

PY - 2013/1

Y1 - 2013/1

N2 - The management of open fractures and delayed or non unions continue to be complicated by high rates of treatment failure and significant patient disability and dissatisfaction. The use of bone morphogenetic proteins (BMPs) in the treatment of these injuries has been assessed by several authors. BMPs induce the process of bone healing by recruiting bone-forming cells to the area of lesion. The use of BMP currently has two FDA-approved indications: treatment of open tibial fractures treated with intramedullary fixation and treatment of tibia long bone non-union. Despite this limited target, off-label BMP use continues to push the spectrum for new applications. This review describes the current evidence for the use of BMPs in open fractures and non-unions.

AB - The management of open fractures and delayed or non unions continue to be complicated by high rates of treatment failure and significant patient disability and dissatisfaction. The use of bone morphogenetic proteins (BMPs) in the treatment of these injuries has been assessed by several authors. BMPs induce the process of bone healing by recruiting bone-forming cells to the area of lesion. The use of BMP currently has two FDA-approved indications: treatment of open tibial fractures treated with intramedullary fixation and treatment of tibia long bone non-union. Despite this limited target, off-label BMP use continues to push the spectrum for new applications. This review describes the current evidence for the use of BMPs in open fractures and non-unions.

KW - Bone morphogenetic protein (BMP)

KW - Fracture healing

KW - Non-union

KW - Open fracture

UR - http://www.scopus.com/inward/record.url?scp=84872864701&partnerID=8YFLogxK

U2 - 10.1016/S0020-1383(13)70008-1

DO - 10.1016/S0020-1383(13)70008-1

M3 - Article

SN - 0020-1383

VL - 44

SP - S34-S39

JO - Injury

JF - Injury

IS - SUPPL.1

ER -

Clinical applications of growth factors in bone injuries: Experience with BMPs

Abstract

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo